Ушбу иш иқтибос қилган ишлар

100 та иш

Иш: Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy

Cancer stem cells: advances in knowledge and implications for cancer therapy
Xianjing Chu, Wentao Tian, Jiaoyang Ning +7
Мақола20248 иқтибос
ABI
Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence
Beatrice Aramini, Valentina Masciale, Giulia Grisendi +8
Шарҳ мақола20226 иқтибос
ABI
Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions
Kaveh Hadiloo, Parsa Mostanadi, Ali Asadzadeh +2
Шарҳ мақола20256 иқтибос
ABI
Targeting cancer stem cell pathways for cancer therapy
Liqun Yang, Pengfei Shi, Gaichao Zhao +8
Шарҳ мақола20205 иқтибос
ABI
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
Xinyi Xiao, Shengkang Huang, Sifei Chen +4
Шарҳ мақола20215 иқтибос
ABI
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Lei Peng, Giacomo Sferruzza, Luojia Yang +2
Шарҳ мақола20245 иқтибос
ABI
Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance
Gh. Rasool Bhat, Itty Sethi, Hana Q. Sadida +14
Шарҳ мақола20245 иқтибос
ABI
The clinical landscape of CAR NK cells
Lasse Vedel Jørgensen, Emil Birch Christensen, Mike Bogetofte Barnkob +1
Шарҳ мақола20255 иқтибос
ABI
The tumor microenvironment’s role in the response to immune checkpoint blockade
Konstantinos Aliazis, Anthos Christofides, Rushil Shah +4
Шарҳ мақола20254 иқтибос
ABI
Long-term outcomes following CAR T cell therapy: what we know so far
Kathryn M. Cappell, James N. Kochenderfer
Шарҳ мақола20233 иқтибос
ABI
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Marek Z. Wojtukiewicz, Magdalena M. Rek, Kamil Karpowicz +7
Шарҳ мақола20213 иқтибос
ABI
Cancer Stem Cell Plasticity Drives Therapeutic Resistance
Mary R. Doherty, Jacob Smigiel, Damian J. Junk +1
Шарҳ мақола20163 иқтибос
ABI
From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
Eleonora Pinto, Lisa A. Lione, Mirco Compagnone +8
Шарҳ мақола20253 иқтибос
ABI
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang, Ming Chen, Hong Nie +1
Шарҳ мақола20192 иқтибос
ABI
Microenvironmental regulation of therapeutic response in cancer
Florian Klemm, Johanna A. Joyce
Шарҳ мақола20142 иқтибос
ABI
The NF-κB Pathway and Cancer Stem Cells
Amanda L. Rinkenbaugh, Albert S. Baldwin
Шарҳ мақола20162 иқтибос
ABI
Targeting cancer stem cells in drug discovery: Current state and future perspectives
Fangyu Du, Qifan Zhou, Wenjiao Sun +1
Шарҳ мақола20192 иқтибос
ABI
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells
Deobrat Dixit, Briana C. Prager, Ryan C. Gimple +16
Мақола20202 иқтибос
ABI
Cellular and molecular mechanisms of plasticity in cancer
Stefan Torborg, Zhuxuan Li, Jason E. Chan +1
Шарҳ мақола20222 иқтибос
ABI
Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment
Vinicio Melo, Edwin Bremer, John D. Martin
Шарҳ мақола20222 иқтибос
ABI
Metabolic challenges and interventions in CAR T cell therapy
Jhan-Jie Peng, Limei Wang, Zhiyu Li +2
Шарҳ мақола20232 иқтибос
ABI
CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance
Diane Coursier, Fernando Calvo
Шарҳ мақола20242 иқтибос
ABI
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function
Matthew Bell, Stephen Gottschalk
Шарҳ мақола20212 иқтибос
ABI
Improving CAR T-Cell Persistence
Violena Pietrobon, Lauren A. Todd, Anghsumala Goswami +3
Шарҳ мақола20212 иқтибос
ABI
Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies
Neha R. Raghani, Mehul R. Chorawala, Mayuresh Mahadik +3
Мақола20242 иқтибос
ABI